BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets
German Biotech Sets Sights On Cancer Cell Therapies
Executive Summary
The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.
You may also be interested in...
Gilead Teases Big Cancer Drug Readouts In Second Half
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.
Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.